CBIO
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Crescent Biopharma, Inc. (CBIO) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.7) | B (3.2) | C+ (2.5) | C (2.4) | A+ (5.0) | B (3.2) |
| 2026-11-04 | C+ (2.8) | B- (3.1) | C+ (2.5) | C (2.3) | A+ (5.0) | B- (3.1) |
| 2026-10-28 | C+ (2.8) | B- (3.1) | C+ (2.5) | C- (2.1) | A+ (5.0) | B- (3.1) |
| 2026-10-21 | C+ (2.8) | B- (3.1) | C+ (2.5) | C- (2.1) | A+ (5.0) | B- (3.1) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe